The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

The Value of Screening for "High on Treatment Platelet Reactivity" in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Study Overview

• Status: Recruiting
• Conditions: Peripheral Arterial Occlusive Disease; Peripheral Vascular Disease; Peripheral Artery Disease; Clopidogrel, Poor Metabolism of; Artery Disease
• Intervention / Treatment: Diagnostic test: Point of care screening for HPR; Drug: Ticagrelor 90mg

Detailed Description

Peripheral arterial disease (PAD) affects millions of people worldwide. Management of PAD has evolved from open surgery to an endovascular first approach leading to increased volume of endovascular interventions. Endovascular femoropopliteal intervention has emerged as a standard treatment for symptomatic PAD with acceptable patency rates.

Histologic observation of bare metal stents with early failure shows association with platelet rich thrombus, high counts of platelets, and neutrophils associated with stent struts. Additionally, high inflation pressures associated with balloon angioplasty often causes local tissue damage leading to platelet activation. These findings led to studies targeting platelet activation following endovascular treatment showing improved outcomes in patients receiving stronger platelet inhibition.

The current standard of care is prescription of dual antiplatelet therapy (DAPT) for femoropopliteal angioplasty or stenting. DAPT is active use of any two antiplatelet agents, often low dose aspirin plus P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel). There is improved stent patency and reduced adverse cardiovascular events in patients taking DAPT versus aspirin monotherapy.

Clopidogrel is the most common additional antiplatelet agent prescribed, but 4-65% of patients taking clopidogrel fail to achieve clinically expected platelet inhibition. This persistent platelet reactivity despite compliant antiplatelet use is commonly referred to as high on-treatment platelet reactivity (HPR), and increases risk of endovascular intervention failure and associated adverse clinical events in these patients. Clopidogrel is a pro-drug metabolized by CYP2C19 enzyme into its active form. Failure to respond appropriately to clopidogrel is largely due to genetic polymorphisms within CYP2C19 enzyme resulting in variable metabolization of clopidogrel into the active metabolite.

Alternative antiplatelet medications can overcome HPR through different metabolic pathways, but unfortunately at a significantly higher cost. Of these, ticagrelor is often used to overcome HPR for patients taking clopidogrel with favorable outcomes. However, regional cost for ticagrelor is $352.50 compared to $1.96 for clopidogrel. Cost and bleeding concerns among providers have prevented widespread use. Overall, there is paucity of evidence looking at HPR and lower extremity arterial endovascular interventions without consensus or guidelines on how to address this problem. Thus, the investigators propose an unblinded, randomized controlled trial in patients having femoropopliteal angioplasty or stenting comparing two strategies: 1. testing and treating for HPR versus 2. guideline based therapy without testing for HPR.

• Study Type: Interventional
• Enrollment (Estimated): 296
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Kyle Markel; Phone Number: 412-802-3031; Email: markelkm2@upmc.edu

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Recruiting
      • University of Pittsburgh Medical Center
      • Contact: Kyle Markel

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Peripheral arterial disease
• Planned angioplasty or stenting of superficial femoral artery or popliteal artery.

Exclusion Criteria:

• Patients treated on an emergency basis
• Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)
• Planned intervention at site exclusive of superficial femoral artery or popliteal artery
• Planned re-stenting at site of prior stent placement
• Planned re-angioplasty at site of prior angioplasty
• Known inability to tolerate antiplatelet regimen before enrollment
• Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center
• Current use of prasugrel or ticlopidine
• Current use of oral anticoagulation medication
• Pregnant patients

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental: screening/treating for HPR; Participants randomized to this arm will be screened and treated for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.	Diagnostic test: Point of care screening for HPR; HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234; Drug: Ticagrelor 90mg; Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
No Intervention: Control: guideline based therapy; Participants randomized to this arm will receive usual care without screening for HPR. Pharmacogenetics testing for CYP2C19 polymorphisms will be collected, stored, and analyzed at study completion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of participants with primary patency	primary patency is freedom from re-intervention, freedom from complete vessel occlusion, freedom from >50% restenosis with duplex ultrasound or freedom from >70% restenosis with computed tomography angiography	one year from intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
proportion of participants with amputation	Freedom from new amputation on the lower extremity intervened on during study	one year from intervention
Correlation of HPR testing results	Correlation of HPR results between VerifyNow and CYP2C19 pharmacogenetics testing	after study completion
Major adverse cardiovascular events	Any new stroke, myocardial infarction, death during study	one year from intervention

Collaborators and Investigators

• Sponsor: Marissa Jarosinski

Study record dates

Study Major Dates

• Study Start (Actual): August 9, 2019
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: July 1, 2019
• First Submitted That Met QC Criteria: July 1, 2019
• First Posted (Actual): July 5, 2019

Study Record Updates

• Last Update Posted (Actual): January 5, 2024
• Last Update Submitted That Met QC Criteria: January 3, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Arteriosclerosis; Atherosclerosis; Vascular Diseases; Peripheral Arterial Disease; Peripheral Vascular Diseases; Arterial Occlusive Diseases; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Ticagrelor
• Other Study ID Numbers: STUDY19030453

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes